Literature DB >> 20053137

Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities.

Holly Hagan1, Enrique R Pouget, Ian T Williams, Richard L Garfein, Steffanie A Strathdee, Sharon M Hudson, Mary H Latka, Lawrence J Ouellet.   

Abstract

BACKGROUND. In studies of hepatitis C virus (HCV) seroconversion in injection drug users (IDUs), some have questioned whether underreporting of syringe sharing, a stigmatized behavior, has led to misattribution of HCV risk to other injection-related behaviors. METHODS. IDUs aged 15-30 years who were seronegative for human immunodeficiency virus and HCV antibodies were recruited into a prospective study in 5 US cities. Behavioral data were collected via computer-assisted self-interviewing to reduce socially desirable reporting. Hazard ratios (HRs) were estimated to assess associations between behavior and HCV seroconversion. Because the shared use of cookers, cottons, and rinse water was highly correlated, a summary variable was created to represent drug preparation equipment sharing. RESULTS. Among 483 IDUs who injected during the period covered by the follow-up assessments, the incidence of HCV infection was 17.2 cases per 100 person years; no HIV seroconversions occurred. Adjusting for confounders, the shared use of drug preparation equipment was significantly associated with HCV seroconversion (adjusted HR, 2.66; 95% confidence interval, 1.03-23.92), but syringe sharing was not (adjusted HR, 0.91). We estimated that 37% of HCV seroconversions in IDUs were due to the sharing of drug preparation equipment. CONCLUSIONS. Associations between sharing drug preparation equipment and HCV seroconversion are not attributable to underascertainment of syringe sharing. Avoiding HCV infection will require substantial reductions in exposure to all sources of contaminated blood.

Entities:  

Mesh:

Year:  2010        PMID: 20053137     DOI: 10.1086/649783

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  70 in total

Review 1.  Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipment.

Authors:  Enrique R Pouget; Holly Hagan; Don C Des Jarlais
Journal:  Addiction       Date:  2012-04-17       Impact factor: 6.526

2.  Injecting risk behavior among traveling young injection drug users: travel partner and city characteristics.

Authors:  Martha E Montgomery; Robin S Fatch; Jennifer L Evans; Michelle Yu; Peter J Davidson; Kimberly Page; Judith A Hahn
Journal:  J Urban Health       Date:  2013-06       Impact factor: 3.671

3.  Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.

Authors:  B Jacka; B C Bray; T L Applegate; B D L Marshall; V D Lima; K Hayashi; K DeBeck; J Raghwani; P R Harrigan; M Krajden; J S G Montaner; J Grebely
Journal:  J Viral Hepat       Date:  2017-09-04       Impact factor: 3.728

4.  Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated.

Authors:  Meghan D Morris; Ali Mirzazadeh; Jennifer L Evans; Alya Briceno; Phillip Coffin; Judith A Hahn; Kimberly A Page
Journal:  Drug Alcohol Depend       Date:  2019-02-27       Impact factor: 4.492

5.  Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada.

Authors:  Brendan Jacka; Tanya Applegate; Art F Poon; Jayna Raghwani; P Richard Harrigan; Kora DeBeck; M-J Milloy; Mel Krajden; Andrea Olmstead; Jeffrey B Joy; Brandon D L Marshall; Kanna Hayashi; Oliver G Pybus; Viviane Dias Lima; Gkikas Magiorkinis; Julio Montaner; Francois Lamoury; Gregory J Dore; Evan Wood; Jason Grebely
Journal:  J Hepatol       Date:  2016-02-26       Impact factor: 25.083

6.  Development and validation of a novel scale for measuring interpersonal factors underlying injection drug using behaviours among injecting partnerships.

Authors:  Meghan D Morris; Torsten B Neilands; Erin Andrew; Lisa Maher; Kimberly A Page; Judith A Hahn
Journal:  Int J Drug Policy       Date:  2017-08-09

7.  Barriers to practicing risk reduction strategies among people who inject drugs.

Authors:  Kristina T Phillips
Journal:  Addict Res Theory       Date:  2015-07-21

8.  Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.

Authors:  Long Zhang; David D Celentano; Nguyen Le Minh; Carl A Latkin; Shruti H Mehta; Constantine Frangakis; Tran Viet Ha; Tran Thi Mo; Teerada Sripaipan; Wendy W Davis; Vu Minh Quan; Vivian F Go
Journal:  Eur J Gastroenterol Hepatol       Date:  2015-05       Impact factor: 2.566

9.  Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.

Authors:  Matthew J Akiyama; Charles M Cleland; John A Lizcano; Peter Cherutich; Ann E Kurth
Journal:  Lancet Infect Dis       Date:  2019-09-17       Impact factor: 25.071

10.  Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users.

Authors:  Jennifer R Havens; Michelle R Lofwall; Simon D W Frost; Carrie B Oser; Carl G Leukefeld; Richard A Crosby
Journal:  Am J Public Health       Date:  2012-11-15       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.